Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Fabian Proft, Murat Torgutalp, Burkhard Muche, Valeria Rios Rodriguez, Joachim Listing, Mikhail Protopopov, Judith Rademacher, Hildrun Haibel, Laura Spiller, Anne-Katrin Weber, Maryna Verba, Jan Brandt-Juergens, Uta Kiltz, Maren Sieburg, Swen Jacki, Joachim Sieper, Denis Poddubnyy
OBJECTIVES: The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years. METHODS: R-axSpA patients, having risk factors for radiographic progression (high disease activity plus C reactive protein >5 mg/L and/or ≥1 syndesmophyte(s)), underwent a 12-week run-in phase with GOL 50 mg every 4 weeks...
January 16, 2024: Annals of the Rheumatic Diseases
#22
JOURNAL ARTICLE
Yonghao Cao, Bohdan P Harvey, Liang Jin, Susan Westmoreland, Jing Wang, Munish Puri, Yingli Yang, Holly M Robb, Sultan Tanriverdi, Chenqi Hu, Xue Wang, Xiaofeng Xin, Yingchun Liu, Michael P Macoritto, Kathleen M Smith, Yu Tian, Kevin White, Timothy R D J Radstake, Zehra Kaymakcalan
Adalimumab but neither etanercept nor certolizumab-pegol has been reported to induce a wound-healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression, which may underlie the differences in efficacy between various TNF-α inhibitors in impaired wound healing in patients with hidradenitis suppurativa, a chronic inflammatory skin disease. To examine and compare the efficacy of various TNF inhibitors in cutaneous wound healing in vivo, a human TNF knock-in Leprdb/db mouse model was established to model the impaired cutaneous wound healing as seen in hidradenitis suppurativa...
January 2024: JID innovations
#23
JOURNAL ARTICLE
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, Rubén Sánchez-Aldehuelo, Montserrat Rivero, Marisa Iborra, María González-Vivo, Isabel Vera, Luisa de Castro, Luis Bujanda, Manuel Barreiro-de Acosta, Carlos González-Muñoza, Xavier Calvet, José Manuel Benítez, Mónica Llorente-Barrio, Gerard Surís, Fiorella Cañete, Lara Arias-García, David Monfort, Andrés Castaño-García, Francisco Javier Garcia-Alonso, José M Huguet, Ignacio Marín-Jímenez, Rufo Lorente, Albert Martín-Cardona, Juan Ángel Ferrer, Patricia Camo, Javier P Gisbert, Ramón Pajares, Fernando Gomollón, Jesús Castro-Poceiro, Jair Morales-Alvarado, Jordina Llaó, Andrés Rodríguez, Cristina Rodríguez, Pablo Pérez-Galindo, Mercè Navarro, Nuria Jiménez-García, Marta Carrillo-Palau, Isabel Blázquez-Gómez, Eva Sesé, Pedro Almela, Patricia Ramírez de la Piscina, Carlos Taxonera, Iago Rodríguez-Lago, Lidia Cabrinety, Milagros Vela, Miguel Mínguez, Francisco Mesonero, María José García, Mariam Aguas, Lucía Márquez, Marisol Silva Porto, Juan R Pineda, Koldo García-Etxebarría, Federico Bertoletti, Eduard Brunet, Míriam Mañosa, Eugeni Domènech
BACKGROUND: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. OBJECTIVES: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. DESIGN: Retrospective observational study. METHODS: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially)...
2024: Therapeutic Advances in Gastroenterology
#24
JOURNAL ARTICLE
Natsuki Ishida, Kenichi Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto
Anti-tumor necrosis factor (TNF) -α antibodies, including infliximab (IFX), adalimumab (ADA), and golimumab, which were the first biologic therapeutic agents, have a crucial position in advanced therapy for ulcerative colitis (UC). We aimed to investigate serum albumin (Alb) change as a prognostic factor for the therapeutic effect of ADA in UC. Thirty-four patients with UC treated with ADA were enrolled in this study and were divided into failure and non-failure groups. Biological data, such as Alb were compared between the two groups...
2024: PloS One
#25
JOURNAL ARTICLE
Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.
Agnieszka Przygocka, Gian Marco Berti, Anita Campus, Francesco Tondolo, Gisella Vischini, Benedetta Fabbrizio, Gaetano La Manna, Olga Baraldi
BACKGROUND: We observe the increasing use of tumor necrosis factor (TNF) inhibitors in patients affected by chronic inflammatory diseases. These drugs provide good control of symptoms, contributing to significant improvement in the quality of life in individuals with high disease burden. On the other hand, along with their wider use and longer follow-up periods the number of reports regarding their adverse effects is also increasing. The reported complications include drug-induced vasculitis with possible kidney involvement...
December 20, 2023: BMC Nephrology
#26
JOURNAL ARTICLE
Daisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, Katsuyoshi Ando, Mikihiro Fujiya, Takahiro Ito, Shigeru Furukawa, Atsuo Maemoto, Takehiko Katsurada, Shiro Hinotsu, Noriko Sato, Naomi Mizuno, Yoshiko Ikawa, Hiroshi Nakase
INTRODUCTION: There have been limited reports on the clinical efficacy of golimumab (GLM) in Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to explore the real-life effectiveness and factors associated with response to GLM in Japanese patients with UC. METHODS: This observational, retrospective, multicenter study was conducted in hospitals with expertise in inflammatory bowel disease treatment. Sixty-three patients treated with GLM and active UC were included in the analysis...
December 2023: Inflammatory Intestinal Diseases
#27
JOURNAL ARTICLE
Sandra M Lord, Henry T Bahnson, Carla J Greenbaum, David R Liljenquist, John Virostko, Cate Speake
Studies of new therapies to preserve insulin secretion in early type 1 diabetes require several years to recruit eligible subjects and to see a treatment effect; thus, there is interest in alternative study designs to speed this process. Most people with longstanding type 1 diabetes no longer secrete insulin. However, studies from pancreata of those with longstanding T1D show that beta cells staining for insulin can persist for decades after diagnosis, and this is paralleled in work showing proinsulin secretion in individuals with longstanding disease; collectively this suggests that there is a reserve of alive but "sleeping" beta cells...
2023: PloS One
#28
JOURNAL ARTICLE
Bayram Farisogullari, Eduardo José Ferreira Santos, Emma Dures, Rinie Geenen, Pedro M Machado
OBJECTIVE: To identify the best evidence on the efficacy of pharmacological interventions in reducing fatigue in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and to summarise their safety in the identified studies to inform European Alliance of Associations for Rheumatology recommendations for the management of fatigue in people with I-RMDs. METHODS: Systematic review of adults with I-RMDs conducted according to the Cochrane Handbook...
December 6, 2023: RMD Open
#29
JOURNAL ARTICLE
Kenji Takami, Shigeyoshi Tsuji
Although biologics have their own characteristics, there are no clear criteria for selecting them to treat the patients with rheumatoid arthritis. To assist in selecting biologics, we investigated the retention rates of biologics at our institution. We examined retention rates, and reasons for dropout for biologics in 393 cases and 605 prescriptions (of which 378 prescriptions were as naive) at our hospital since October 2003. Throughout the entire course of the study, etanercept (ETN) was the most frequently used biologic, followed by adalimumab (ADA) and tocilizumab (TCZ)...
December 1, 2023: Scientific Reports
#30
REVIEW
Marjan Assefi, Kai-Uwe Lewandrowski, Morgan Lorio, Rossano Kepler Alvim Fiorelli, Stefan Landgraeber, Alireza Sharafshah
BACKGROUND: Methotrexate (MTX), sulfonamides, hydroxychloroquine, and leflunomide have consistently resulted in remission with relatively mild to moderate adverse effects in patients with rheumatoid arthritis (RA). Modern medications outperform traditional treatments in that they target the pathological processes that underlie the development of RA. METHODS: Following PRISMA guidelines, the authors accomplished a systematic review of the clinical efficacy of RA drugs, including the biologics such as Tumor Necrosis Factor-alpha inhibitors (TNF-α i) like Etanercept, Infliximab, Golimumab, and Adalimumab, kinase inhibitors (JAK inhibitors including Baricitinib and Tofacitanib), SyK inhibitors like Fos-tamatinib, MAPK inhibitors such as Talmapimod, T-cell inhibitors (Abatacept), IL6 blockers (Tocilizumab), and B cells depleters (Rituximab)...
October 29, 2023: Journal of Personalized Medicine
#31
MULTICENTER STUDY
Fiorenzo Santoleri, Ruggero Lasala, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco Gambera, Isabella Martignoni, Valentina Montresor, Francesco De Vita, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli, Alberto Costantini
OBJECTIVES: The objective was to assess the adherence, persistence, and costs of bDMARDs through a multicentre study of nine Italian hospital pharmacies. METHODS: The drugs analysed were Abatacept, Adalimumab, Certolizumab, Etanercept, Golimumab and Tocilizumab.Adult subjects with Rheumatoid Arthritis were considered in the analysis.In this study, we calculated the following metrics: Adherence to treatment was evaluated as dose-intensity, which is the ratio between the amount of medication received and probably taken by the patient at home (Received Daily Dose, RDD) and the amount prescribed by the clinician (Prescribed Daily Dose, PDD)...
December 2023: Current Medical Research and Opinion
#32
REVIEW
Ivan Foeldvari, Harry Petrushkin
INTRODUCTION: The management of refractory juvenile idiopathic associated uveitis (JIAU) or childhood-onset chronic anterior uveitis (CAU) is a challenge. There is no clear consensus or evidence base for to suggest the most appropriate therapy after primary or secondary failure of biweekly adalimumab. In this scenario, most clinicians advocate switching to another anti-tumor necrosis factor alpha inhibitor; however, there are a variety of other disease modifying agents to choose from albeit with a differing levels of evidence...
March 2024: Expert Review of Clinical Immunology
#33
JOURNAL ARTICLE
Marinella Govoni, Anastas Batalov, Dimitrios T Boumpas, Salvatore D'Angelo, Filip De Keyser, Rene-Marc Flipo, Herbert Kellner, Hermine Leroi, Ahmed Khalifa
OBJECTIVES: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients often experience secondary non-response to a first-line tumour necrosis factor alpha inhibitor (TNFαi). This pooled analysis of six observational studies in Europe (GO-BEYOND program) provides an estimate of second-line golimumab (GLM) effectiveness for these rheumatic diseases. METHODS: The GO-BEYOND studies included common disease-specific endpoints allowing for a pooled analysis...
November 15, 2023: Clinical and Experimental Rheumatology
#34
JOURNAL ARTICLE
Naram Khalayli, Yara Hodifa, Raghad Tarcha, Amr Hodaifa, Maysoun Kudsi
INTRODUCTION: Systemic sclerosis is a connective tissue condition presented with clinical manifestations, including ocular involvement in a small percentage. A few cases of uveitis were described in the literature, especially in CREST syndrome. CASE PRESENTATION: The authors reported a case of a 48-year-old male with a blurred vision in his left eye that diagnosed with recurrent uveitis in the setting of CREST syndrome, treated with prednisolone, methotrexate, and golimumab, with improvement...
November 2023: Annals of Medicine and Surgery
#35
JOURNAL ARTICLE
Menglong Zou, Wei Zhang, Ying Zhu, Yin Xu
Cuproptosis has been reported to affect a variety of diseases. Therefore, we aimed to examine the role of cuproptosis-related genes in active ulcerative colitis (UC). We acquired 2 datasets of active UC from the Gene Expression Omnibus database and created immune cell infiltrations to research immune cell dysregulation. Based on the cuproptosis gene set and differentially expressed genes (DEGs), we identified the differentially expressed genes of cuproptosis (CuDEGs). We then used 2 machine learning methods to screen hub CuDEGs...
October 27, 2023: Medicine (Baltimore)
#36
JOURNAL ARTICLE
Irene Soleto, Cristina Ramirez, Cristina Gómez, Montse Baldan-Martin, Macarena Orejudo, Jorge Mercado, María Chaparro, Javier P Gisbert
Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn's disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear...
October 18, 2023: Biomedicines
#37
JOURNAL ARTICLE
L C Berkhout, M J l'Ami, S Kruithof, E H Vogelzang, F Hooijberg, M H Hart, A E H Bentlage, D Thomas, S Vermeire, G Vidarsson, A Ten Brinke, M T Nurmohamed, G J Wolbink, T Rispens
BACKGROUND AND PURPOSE: Millions of patients with inflammatory diseases are treated with TNF inhibitors (TNFi). Individual treatment response varies, in part related to variable drug clearance. The role of TNF-TNFi complexes in clearance of the different TNFi is controversial. Moreover, mechanistic insight into the structural aspects and biological significance of TNF-TNFi complexes is lacking. We hypothesized a role for Fc-mediated clearance of TNF-TNFi immune complexes. Therefore, we investigated circulating TNF-TNFi complexes upon treatment with certolizumab - lacking Fc tails - in comparison to adalimumab, golimumab, infliximab and etanercept...
October 20, 2023: British Journal of Pharmacology
#38
Hae Chan Lee, Yiyoung Kwon, Eun Sil Kim, Soomin Ahn, Yon Ho Choe, Mi Jin Kim
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab...
May 2023: Annals of Dermatology
#39
JOURNAL ARTICLE
Zakaria Alameddine, Racha Abi Melhem, Reem Dimachkie, Hussein Rabah, Hamed Chehab, Michel El Khoury, Faris Qaqish, Dimitre Stefanov, Suzanne El-Sayegh
INTRODUCTION: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body's immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. METHODS: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis...
September 22, 2023: Journal of Clinical Medicine
#40
MULTICENTER STUDY
Makoto Naganuma, Taku Kobayashi, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki, Shinichiro Yoshioka, Shingo Kato, Masayuki Saruta, Shinji Tanaka, Eriko Yasutomi, Kaoru Yokoyama, Kei Moriya, Yoshikazu Tsuzuki, Makoto Ooi, Mikihiro Fujiya, Atsushi Nakazawa, Takayuki Abe, Tadakazu Hisamatsu
BACKGROUND: This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe ulcerative colitis (ASUC). METHODS: In total, 221 patients with ASUC were enrolled between August 2020 and July 2021. The primary endpoint was clinical remission (CR, defined as a patient-reported outcome score < 2 with no blood in the stool) rate on Day 7 and 14 in hospitalized patients who received corticosteroids (CS) and AT...
December 2023: Journal of Gastroenterology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
